Canopy’s stock reversed on earnings after seeing a rally sparked by the possibility of marijuana reform in the U.S.

Alliance Global Partners analyst Aaron Grey lowered the firm’s price target on Canopy Growth (CGC) to C$4 from C$7 and keeps a Neutral rating ...

Canopy Growth Corporation’s CGC share price has surged by 22.22%, which has investors questioning if this is right time to sell.

Because of this, empirical studies indicate a strong correlation between trends in earnings estimate revisions and short-term stock price movements. For the current quarter, Canopy Growth is ...

Canopy Growth Q3 sales hit C$74.76 million, surpassing estimates. Medical cannabis revenue rose 16%, while adjusted EBITDA loss improved 61% year-over-year.

Be cautious ahead of Canopy Growth Corporation's FQ3 results, as weak financials and low margins may hinder stock performance ...

Aurora Cannabis, Canopy Growth, Tilray, Gibraltar Industries, and Turning Point Brands are the five Cannabis stocks to watch ...

Not only does Canopy Growth still have a lot of debt remaining, its cash flow from operations continues to be negative. Often, tangible book value can help support a stock price, but this doesn't ...